About this trial
This is a prospective, observational, multicenter study aimed at characterizing tricuspid valve remodeling in patients with atrial fibrillation (AF) without significant tricuspid regurgitation (TR), in relation to AF burden progression.
Eligibility criteria
Qualifiers
Consecutive patients with atrial fibrillation (paroxysmal or persistent) undergoing transthoracic echocardiography (TTE) prior to AF ablation with acquisition of a 3D TV dataset.
all consecutive patients with structurally normal hearts and no history of AF or;
moderate atrial functional tricuspid regurgitation and AF, in the absence of significant left-sided valvular disease or prior valvular surgery.
Disqualifiers
Moderate or greater TR assessed using a multiparametric approach;
Arrhythmias other than AF;
Prior AF ablations;
Rapid ventricular response (average HR >110 bpm) during baseline TTE;
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
Centro Cardiologico Monzino
Lead sponsor
Istituto Clinico Humanitas
Collaborator